Vancouver, British Columbia--(Newsfile Corp. - September 27, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2…
Continues customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancersBOCA RATON, Fla., Sept. 25, 2024…
Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumorsLEXINGTON, Mass., Sept. 24,…
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept.…
-Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in…
–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities…
ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company…
Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society 2024…
MyRisk®, FirstGene®, Prequel®, and Foresight® studies among 10 datasets to be shared by MyriadSALT LAKE CITY, Sept. 18, 2024 (GLOBE…